GLIMMUNE THERAPEUTICS
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

GLIMMUNE THERAPEUTICS Trademark

Serial Number: 97917473

GLIMMUNE THERAPEUTICS is a trademark filed by Glenmark Pharmaceuticals Limited on May 2, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Glenmark Pharmaceuticals Limited (11 trademarks)

2/B Mahalaxmi Chamber 22
Mumbai , IN

Entity Type: 03

Trademark Details

Filing Date

May 2, 2023

Registration Date

Not Registered

Published for Opposition

March 5, 2024

Goods & Services

Pharmaceutical preparations for human use for the treatment of respiratory disorders; nasal spray preparations; Opium alkaloid preparations; pharmaceutical anti-allergic preparations and substances; pharmaceutical antitussive-cold preparations; pharmaceutical preparation for the treatment of gout; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for animal skincare; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; pharmaceutical preparations for skin care; pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system, for the treatment of inflammatory disorders, for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics, antifungal preparations and vaccines; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of heart rhythm disorders; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for treating allergic rhinitis and asthma; pharmaceutical preparations for treating diabetes; pharmaceutical preparations for treating skin disorders; pharmaceutical preparations for use in chemotherapy; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for wounds; pharmaceutical preparations, namely, antidepressants; pharmaceutical preparations, namely, appetite suppressants; pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations, namely, anticoagulants; pharmaceutical products and preparations against dry skin caused by pregnancy; pharmaceutical products and preparations for chloasma; pharmaceutical products and preparations for hydrating the skin during pregnancy; pharmaceutical products and preparations for pregnancy blemishes; pharmaceutical products and preparations for preventing skin blemishes during pregnancy; pharmaceutical products and preparations to prevent stretch marks; pharmaceutical products and preparations to prevent swelling in the legs; pharmaceutical products for ophthalmological use; pharmaceutical products for skin care for animals; pharmaceutical products for the treatment of bone diseases; pharmaceutical products for the treatment of joint disease; pharmaceutical products for the treatment of viral and infectious diseases; pharmaceutical products for treating respiratory diseases and asthma; pharmaceutical skin lotions; pharmaceutical solutions used in dialysis; pharmaceuticals for the treatment of erectile dysfunction; pharmaceuticals, namely, anti-infectives; pharmaceuticals, namely, antihelmintics; pharmaceuticals, namely, inducers of erections; pharmaceuticals, namely, lipid lowering agents; preparation for the relief of pain; preparations for the treatment of asthma

Filing History

ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Dec 2, 2024 MAB6
ABANDONMENT - NO USE STATEMENT FILED
Dec 2, 2024 ABN6
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 30, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 5, 2024 NPUB
PUBLISHED FOR OPPOSITION
Mar 5, 2024 PUBO
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 14, 2024 NPUB
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 14, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 26, 2024 CNSA
ASSIGNED TO EXAMINER
Jan 23, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 31, 2023 NWOS
NEW APPLICATION ENTERED
May 5, 2023 NWAP